Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.63)
# 3,884
Out of 4,876 analysts
55
Total ratings
29.17%
Success rate
-29.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $3.69 | +198.51% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $13.11 | +136.46% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.46 | +1,201.37% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $4.21 | +398.81% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $2.60 | +92.31% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.31 | +1,121.37% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $10 | $0.23 | +4,266.81% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $10.18 | +145.58% | 2 | May 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $200 | $0.93 | +21,461.02% | 1 | Feb 8, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $7 | $1.09 | +545.16% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.15 | +769.57% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $8.03 | +647.66% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $0.32 | +1,749.00% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.09 | +144.50% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $0.71 | +33,522.86% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $7.09 | +2,467.00% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.24 | +33,485.22% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.49 | +703.21% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.46 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.98 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.42 | +322.54% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.71 | +172.37% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $9.22 | +113,782.86% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.17 | +1,605.07% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $29.68 | +910.78% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $521.00 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $70.81 | +25.69% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $126.71 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $0.99 | +100,910.10% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $2.25 | +14,833.33% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.97 | +506.06% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $3.69
Upside: +198.51%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $13.11
Upside: +136.46%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.46
Upside: +1,201.37%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $4.21
Upside: +398.81%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $2.60
Upside: +92.31%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.31
Upside: +1,121.37%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $10
Current: $0.23
Upside: +4,266.81%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $10.18
Upside: +145.58%
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $200
Current: $0.93
Upside: +21,461.02%
PMV Pharmaceuticals
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.09
Upside: +545.16%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $1.15
Upside: +769.57%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $8.03
Upside: +647.66%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $0.32
Upside: +1,749.00%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.09
Upside: +144.50%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $0.71
Upside: +33,522.86%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $7.09
Upside: +2,467.00%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.24
Upside: +33,485.22%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $2.49
Upside: +703.21%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.46
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.98
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $1.42
Upside: +322.54%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $7.71
Upside: +172.37%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $9.22
Upside: +113,782.86%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.17
Upside: +1,605.07%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $29.68
Upside: +910.78%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $521.00
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $70.81
Upside: +25.69%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $126.71
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $0.99
Upside: +100,910.10%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $2.25
Upside: +14,833.33%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $2.97
Upside: +506.06%